Prolacta Bioscience, Inc.

Prolacta Bioscience, Inc., headquartered in City of Industry, California, manufactures pasteurized human milk-based nutritional products for neonatal intensive care units as a prime contractor to the Defense Health Agency and Department of Defense medical commands, competing on a full-and-open basis with no set-aside designations across its federal portfolio.

Prolacta is a for-profit manufacturer of goods specializing exclusively in human milk-derived fortifiers, donor human milk, breastmilk supplementation products, and pre-natal infant formulas engineered for extremely low birth weight and critically ill newborns. The company's federal footprint is narrowly focused on military healthcare: all 72 awards in the source data are prime contracts with the Defense Health Agency, the Department of the Army Medical Command, and the Department of the Navy Bureau of Medicine and Surgery, with zero subcontract exposure. Representative work includes a $113,211 BPA call from the Defense Health Agency in March 2026 for pasteurized human milk products; a $24,971 order in November 2025 for breastmilk fortification products at Tripler Army Medical Center; and a $150,000 BPA call from the Department of the Army Medical Command in October 2021 for human milk-based neonatal nutrition products. The company's categorization by NAICS centers on Biological Product Manufacturing (70 awards), with secondary coding in Surgical and Medical Instrument Manufacturing and Special Dietary Foods.

Customer concentration is extreme. The Defense Health Agency accounts for 50 awards and $9.9 million in combined potential value (100% coverage across both award-count and dollar rankings); the Department of the Army Medical Command holds 14 awards worth $6.3 million; and the Department of the Navy Bureau of Medicine and Surgery represents 8 awards worth $1.1 million. The rankings align perfectly, signaling no tension between volume and value—DHA dominates both dimensions. Prolacta operates under three single-award BPAs with the Defense Health Agency: a $1.75 million agreement established in October 2022 with ultimate completion in September 2027; a $1.9 million agreement awarded in December 2024 running through December 2029; and a $500,000 agreement from September 2023 expiring September 2028. Two Army Medical Command BPAs generate the bulk of remaining activity: Blanket Purchase Agreement W81K0222A0010 has generated 27 task orders worth $1.2 million combined potential value, and Blanket Purchase Agreement W81K0217A0025 has produced 12 task orders worth $1 million.

Activity trajectory shows volatility within a small envelope: 7 awards in 2022, climbing to 12 in 2023, declining to 9 in 2024, dropping to 8 in 2025, and 2 awards through mid-2026. Combined potential value across the entire portfolio totals $17.4 million, with $8.9 million obligated (51% realization rate). The recompete cliff is minimal—only 3 awards with ultimate completion dates within the next twenty-four months carry a combined potential value of $86 thousand, presenting negligible near-term recompete exposure. Prolacta holds no government-wide vehicles, agency-wide IDIQs, GWACs, or GSA Schedules; all federal work flows through single-award BPAs held directly with military health system customers. The company has not appeared as a subcontractor in the source data, and no primes name Prolacta as a sub. Prolacta's federal business model is a sole-source or near-sole-source specialty supplier to neonatal units within the military healthcare system, with no diversification across civilian agencies, no teaming or subcontracting relationships, and no pursuit pathway outside DHA and Army Medical Command medical facilities.